Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Humanigen price target raised to $36 from $34 at H.C. Wainwright » 06:07
04/12/21
04/12
06:07
04/12/21
06:07
HGEN

Humanigen

$17.26 /

+0.45 (+2.68%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis raised the firm's price target on Humanigen to $36 from $34 and keeps a Buy rating on the shares. At the end of March, Humanigen announced a topline data readout from its Phase 3 trial evaluating lenzilumab in hospitalized COVID-19 patients, Pantginis tells investors in a research note. A significant takeaway from the announcement is that the study concluded lenzilumab can improve the relative rates of survival, particularly COVID-19 patients that did not require invasive mechanical ventilation by 54%, Pantginis tells investors in a research note. The analyst believes lenzilumab differentiates itself in the space by improving survival outcomes in a diverse COVID-19 patient population.

ShowHide Related Items >><<
HGEN Humanigen
$17.26 /

+0.45 (+2.68%)

HGEN Humanigen
$17.26 /

+0.45 (+2.68%)

03/29/21 JPMorgan
Humanigen upside reaction 'somewhat overdone,' says JPMorgan
03/29/21 RBC Capital
Humanigen lenzilumab update 'an incremental positive' for Avid, says RBC Capital
03/29/21 Roth Capital
Humanigen price target raised to $35 from $25 at Roth Capital
02/23/21 JPMorgan
Humanigen initiated with a Neutral at JPMorgan
HGEN Humanigen
$17.26 /

+0.45 (+2.68%)

  • 31
    Mar
  • 18
    Sep
HGEN Humanigen
$17.26 /

+0.45 (+2.68%)

HGEN Humanigen
$17.26 /

+0.45 (+2.68%)

Friday
Hot Stocks
Humanigen to announce ifabotuzumab data at AACR annual meeting » 07:06
04/09/21
04/09
07:06
04/09/21
07:06
HGEN

Humanigen

$16.79 /

+0.1 (+0.60%)

Humanigen (HGEN)…

Humanigen (HGEN) announced results from the Phase 1 safety and bioimaging trial of its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme, or GBM. In the study, ifabotuzumab demonstrated sensitive, specific, and reproducible targeting of the tumor and tumor microenvironment in all patients. The results will be presented as a poster at the AACR annual meeting, held virtually from April 10-15, and remain available until June 21. The Phase 1 study primarily sought to determine the safety and recommended Phase 2 dose of ifabotuzumab in patients with GBM, the most frequent and lethal primary brain neoplasm, with 5-year survival rates of 10%. The study showed that, at both doses, ifabotuzumab demonstrated highly sensitive, specific, and reproducible targeting of the tumor and tumor microenvironment in all patients. There were no dose-limiting toxicities observed and all adverse events were readily manageable. Additional studies are planned to evaluate ifabotuzumab as an antibody-drug conjugate in solid tumor patients.

ShowHide Related Items >><<
HGEN Humanigen
$16.79 /

+0.1 (+0.60%)

HGEN Humanigen
$16.79 /

+0.1 (+0.60%)

03/29/21 JPMorgan
Humanigen upside reaction 'somewhat overdone,' says JPMorgan
03/29/21 RBC Capital
Humanigen lenzilumab update 'an incremental positive' for Avid, says RBC Capital
03/29/21 Roth Capital
Humanigen price target raised to $35 from $25 at Roth Capital
02/23/21 JPMorgan
Humanigen initiated with a Neutral at JPMorgan
HGEN Humanigen
$16.79 /

+0.1 (+0.60%)

  • 31
    Mar
  • 18
    Sep
HGEN Humanigen
$16.79 /

+0.1 (+0.60%)

HGEN Humanigen
$16.79 /

+0.1 (+0.60%)

Over a week ago
Options
Largest borrow rate increases among liquid names » 08:45
04/05/21
04/05
08:45
04/05/21
08:45
HGEN

Humanigen

$19.20 /

-0.08 (-0.41%)

, ARKK

ARK Innovation ETF

$120.84 /

+0.99 (+0.83%)

, CLVR

Clever Leaves

$10.80 /

+0.465 (+4.50%)

, LGHL

Lion Group

$3.65 /

-0.76 (-17.23%)

, ONCT

Oncternal Therapeutics

$8.35 /

+0.06 (+0.72%)

, GOEV

Canoo

$9.02 /

-0.01 (-0.11%)

, TM

Toyota

$154.12 /

-1.99 (-1.27%)

, TAK

Takeda Pharmaceutical

$18.64 /

+0.375 (+2.05%)

, FAII

Fortress Value Acquisition Corp. II

$10.09 /

+0.115 (+1.15%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Humanigen (HGEN) 19.74% +13.19, ARK Innovation ETF (ARKK) 34.25% +11.23, Clever Leaves (CLVR) 35.09% +8.34, Lion Group Holding Ltd (LGHL) 38.50% +7.70, Oncternal Therapeutics (ONCT) 82.77% +6.08, Burgundy Technology Acquition Corp (BTAQ) 5.62% +4.40, Canoo (GOEV) 16.19% +3.39, Toyota (TM) 3.79% +3.33, Takeda Pharmaceutical (TAK) 7.82% +3.26, and Fortress Value Acquisition Corp II (FAII) 9.11% +3.14.

ShowHide Related Items >><<
TM Toyota
$154.12 /

-1.99 (-1.27%)

TAK Takeda Pharmaceutical
$18.64 /

+0.375 (+2.05%)

ONCT Oncternal Therapeutics
$8.35 /

+0.06 (+0.72%)

LGHL Lion Group
$3.65 /

-0.76 (-17.23%)

HGEN Humanigen
$19.20 /

-0.08 (-0.41%)

GOEV Canoo
$9.02 /

-0.01 (-0.11%)

FAII Fortress Value Acquisition Corp. II
$10.09 /

+0.115 (+1.15%)

CLVR Clever Leaves
$10.80 /

+0.465 (+4.50%)

ARKK ARK Innovation ETF
$120.84 /

+0.99 (+0.83%)

HGEN Humanigen
$19.20 /

-0.08 (-0.41%)

03/29/21 JPMorgan
Humanigen upside reaction 'somewhat overdone,' says JPMorgan
03/29/21 RBC Capital
Humanigen lenzilumab update 'an incremental positive' for Avid, says RBC Capital
03/29/21 Roth Capital
Humanigen price target raised to $35 from $25 at Roth Capital
02/23/21 JPMorgan
Humanigen initiated with a Neutral at JPMorgan
ARKK ARK Innovation ETF
$120.84 /

+0.99 (+0.83%)

CLVR Clever Leaves
$10.80 /

+0.465 (+4.50%)

LGHL Lion Group
$3.65 /

-0.76 (-17.23%)

ONCT Oncternal Therapeutics
$8.35 /

+0.06 (+0.72%)

03/30/21
Fly Intel: Top five analyst initiations
03/30/21 Brookline
Oncternal Therapeutics initiated with a Buy at Brookline
02/23/21 Northland
Northland starts $7 Oncternal Therapeutics at Outperform with $21 target
02/23/21 Northland
Oncternal Therapeutics initiated with an Outperform at Northland
GOEV Canoo
$9.02 /

-0.01 (-0.11%)

03/30/21 Roth Capital
Canoo downgraded to Neutral at Roth Capital on 'complete change in direction'
03/30/21 Roth Capital
Canoo downgraded to Neutral from Buy at Roth Capital
03/11/21 R.F. Lafferty
Canoo initiated with a Buy at R.F. Lafferty
TM Toyota
$154.12 /

-1.99 (-1.27%)

03/30/21 Citi
Toyota resumed with a Buy at Citi
09/14/20 Credit Suisse
Toyota upgraded to Outperform from Neutral at Credit Suisse
09/08/20 Bernstein
Bernstein sees Tesla's current valuation as 'mind-boggling'
07/29/20 Morgan Stanley
Tesla price target raised to $1,050 from $740 at Morgan Stanley
TAK Takeda Pharmaceutical
$18.64 /

+0.375 (+2.05%)

04/05/21 Jefferies
Takeda Pharmaceutical downgraded to Hold from Buy at Jefferies
03/03/21 RBC Capital
Ovid downgraded to Sector Perform at RBC Capital after rally on Takeda deal
01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
FAII Fortress Value Acquisition Corp. II
$10.09 /

+0.115 (+1.15%)

TM Toyota
$154.12 /

-1.99 (-1.27%)

TAK Takeda Pharmaceutical
$18.64 /

+0.375 (+2.05%)

ONCT Oncternal Therapeutics
$8.35 /

+0.06 (+0.72%)

HGEN Humanigen
$19.20 /

-0.08 (-0.41%)

GOEV Canoo
$9.02 /

-0.01 (-0.11%)

  • 31
    Mar
  • 18
    Nov
  • 18
    Sep
  • 28
    Aug
TM Toyota
$154.12 /

-1.99 (-1.27%)

TAK Takeda Pharmaceutical
$18.64 /

+0.375 (+2.05%)

GOEV Canoo
$9.02 /

-0.01 (-0.11%)

TM Toyota
$154.12 /

-1.99 (-1.27%)

TAK Takeda Pharmaceutical
$18.64 /

+0.375 (+2.05%)

HGEN Humanigen
$19.20 /

-0.08 (-0.41%)

GOEV Canoo
$9.02 /

-0.01 (-0.11%)

FAII Fortress Value Acquisition Corp. II
$10.09 /

+0.115 (+1.15%)

CLVR Clever Leaves
$10.80 /

+0.465 (+4.50%)

TAK Takeda Pharmaceutical
$18.64 /

+0.375 (+2.05%)

ONCT Oncternal Therapeutics
$8.35 /

+0.06 (+0.72%)

LGHL Lion Group
$3.65 /

-0.76 (-17.23%)

HGEN Humanigen
$19.20 /

-0.08 (-0.41%)

GOEV Canoo
$9.02 /

-0.01 (-0.11%)

FAII Fortress Value Acquisition Corp. II
$10.09 /

+0.115 (+1.15%)

CLVR Clever Leaves
$10.80 /

+0.465 (+4.50%)

ARKK ARK Innovation ETF
$120.84 /

+0.99 (+0.83%)

ARKK ARK Innovation ETF
$120.84 /

+0.99 (+0.83%)

Syndicate
Humanigen 5M share Secondary priced at $18.50 » 20:20
03/30/21
03/30
20:20
03/30/21
20:20
HGEN

Humanigen

$21.62 /

-0.07 (-0.32%)

The deal priced below the…

The deal priced below the last closing price of $21.67. Jefferies, Credit Suisse and Cantor Fitzgerald are acting as joint book running managers for the offering.

ShowHide Related Items >><<
HGEN Humanigen
$21.62 /

-0.07 (-0.32%)

HGEN Humanigen
$21.62 /

-0.07 (-0.32%)

03/29/21 JPMorgan
Humanigen upside reaction 'somewhat overdone,' says JPMorgan
03/29/21 RBC Capital
Humanigen lenzilumab update 'an incremental positive' for Avid, says RBC Capital
03/29/21 Roth Capital
Humanigen price target raised to $35 from $25 at Roth Capital
02/23/21 JPMorgan
Humanigen initiated with a Neutral at JPMorgan
HGEN Humanigen
$21.62 /

-0.07 (-0.32%)

  • 31
    Mar
  • 18
    Sep
HGEN Humanigen
$21.62 /

-0.07 (-0.32%)

HGEN Humanigen
$21.62 /

-0.07 (-0.32%)

On The Fly
Fly Intel: Wall Street's top stories for Monday » 16:31
03/29/21
03/29
16:31
03/29/21
16:31
NWSA

News Corp.

$25.03 /

-0.7 (-2.72%)

, BA

Boeing

$250.81 /

+5.96 (+2.43%)

, LUV

Southwest

$60.96 /

-0.32 (-0.52%)

, CS

Credit Suisse

$11.38 /

-1.485 (-11.54%)

, NMR

Nomura

$5.68 /

-0.94 (-14.20%)

, PFE

Pfizer

$36.62 /

+0.37 (+1.02%)

, MRNA

Moderna

$123.35 /

-9.8 (-7.36%)

, BNTX

BioNTech

$95.74 /

+0.21 (+0.22%)

, HGEN

Humanigen

$21.69 /

+7.68 (+54.82%)

, HMHC

Houghton Mifflin

$7.11 /

+1.115 (+18.61%)

, CG

Carlyle Group

$36.37 /

-0.37 (-1.01%)

, CLDX

Celldex

$20.50 /

-3.51 (-14.62%)

, GSX

GSX Techedu

$31.84 /

-7.17 (-18.38%)

The major averages were…

ShowHide Related Items >><<
PFE Pfizer
$36.62 /

+0.37 (+1.02%)

NWSA News Corp.
$25.03 /

-0.7 (-2.72%)

NMR Nomura
$5.68 /

-0.94 (-14.20%)

MRNA Moderna
$123.35 /

-9.8 (-7.36%)

LUV Southwest
$60.96 /

-0.32 (-0.52%)

HMHC Houghton Mifflin
$7.11 /

+1.115 (+18.61%)

HGEN Humanigen
$21.69 /

+7.68 (+54.82%)

GSX GSX Techedu
$31.84 /

-7.17 (-18.38%)

CS Credit Suisse
$11.38 /

-1.485 (-11.54%)

CLDX Celldex
$20.50 /

-3.51 (-14.62%)

CG Carlyle Group
$36.37 /

-0.37 (-1.01%)

BNTX BioNTech
$95.74 /

+0.21 (+0.22%)

BA Boeing
$250.81 /

+5.96 (+2.43%)

NWSA News Corp.
$25.03 /

-0.7 (-2.72%)

03/18/21
Fly Intel: Top five analyst upgrades
03/18/21 Guggenheim
Guggenheim upgrades News Corp. to Buy, sees 'significant value' to be unlocked
03/18/21 Guggenheim
News Corp. upgraded to Buy from Neutral at Guggenheim
02/12/21
Fly Intel: Top five analyst upgrades
BA Boeing
$250.81 /

+5.96 (+2.43%)

03/29/21 Goldman Sachs
Boeing resuming 787 deliveries removes overhang, says Goldman Sachs
03/19/21 Susquehanna
Boeing price target raised to $300 from $250 at Susquehanna
03/15/21 Morgan Stanley
Aerospace sector upgraded to Attractive from Cautious at Morgan Stanley
03/15/21 Morgan Stanley
Boeing price target raised to $274 from $250 at Morgan Stanley
LUV Southwest
$60.96 /

-0.32 (-0.52%)

03/23/21
Fly Intel: Top five analyst upgrades
03/23/21 Argus
Southwest upgraded to Buy from Hold at Argus
03/23/21 Argus
Southwest upgraded to Buy from Hold at Argus
03/16/21 Goldman Sachs
Southwest price target raised to $69 from $47 at Goldman Sachs
CS Credit Suisse
$11.38 /

-1.485 (-11.54%)

03/30/21 Citi
Credit Suisse buyback likely suspended on Archegos losses, says Citi
03/29/21 Deutsche Bank
Credit Suisse price target lowered to CHF 15 from CHF 16 at Deutsche Bank
03/29/21
Fly Intel: Top five analyst downgrades
03/29/21 BofA
Credit Suisse downgraded to Neutral from Buy at BofA
NMR Nomura
$5.68 /

-0.94 (-14.20%)

03/29/21 JPMorgan
Nomura downgraded to Underweight from Neutral at JPMorgan
03/09/21 Goldman Sachs
Nomura upgraded to Buy from Neutral at Goldman Sachs
03/01/21 Citi
Nomura upgraded to Neutral from Sell at Citi
PFE Pfizer
$36.62 /

+0.37 (+1.02%)

03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
MRNA Moderna
$123.35 /

-9.8 (-7.36%)

03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
03/01/21 Chardan
Moderna price target raised to $182 from $107 at Chardan
02/26/21 Barclays
Moderna price target raised to $178 from $169 at Barclays
02/26/21 Brookline
Moderna price target raised to $205 from $180 at Brookline
BNTX BioNTech
$95.74 /

+0.21 (+0.22%)

02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
HGEN Humanigen
$21.69 /

+7.68 (+54.82%)

03/29/21 JPMorgan
Humanigen upside reaction 'somewhat overdone,' says JPMorgan
03/29/21 RBC Capital
Humanigen lenzilumab update 'an incremental positive' for Avid, says RBC Capital
03/29/21 Roth Capital
Humanigen price target raised to $35 from $25 at Roth Capital
02/23/21 JPMorgan
Humanigen initiated with a Neutral at JPMorgan
HMHC Houghton Mifflin
$7.11 /

+1.115 (+18.61%)

03/03/21 BMO Capital
Houghton Mifflin price target raised to $6 from $3 at BMO Capital
12/15/20 Citi
Houghton Mifflin price target raised to $3.45 from $3 at Citi
11/24/20 Citi
Houghton Mifflin price target raised to $3 from $2.50 at Citi
10/05/20 Citi
Houghton Mifflin upgraded to Neutral from Sell at Citi
CG Carlyle Group
$36.37 /

-0.37 (-1.01%)

02/24/21 Deutsche Bank
Carlyle Group price target raised to $39 from $37 at Deutsche Bank
02/24/21 Barclays
Carlyle Group price target raised to $39 from $36 at Barclays
02/19/21
Fly Intel: Top five analyst upgrades
02/19/21 Credit Suisse
Carlyle Group upgraded to Outperform from Neutral at Credit Suisse
CLDX Celldex
$20.50 /

-3.51 (-14.62%)

03/29/21 H.C. Wainwright
Celldex selloff on CDX-0159 data 'undeserved,' says H.C. Wainwright
02/23/21 H.C. Wainwright
Celldex price target raised to $36 from $25 at H.C. Wainwright
02/23/21 Cantor Fitzgerald
Celldex price target raised to $35 from $22 at Cantor Fitzgerald
10/19/20 H.C. Wainwright
Celldex price target raised to $25 from $16 at H.C. Wainwright
GSX GSX Techedu
$31.84 /

-7.17 (-18.38%)

03/29/21
Fly Intel: Top five analyst upgrades
03/29/21 Citi
Citi double upgrades GSX Techedu to Buy after Friday's 'overdone' selloff
03/29/21 Citi
GSX Techedu upgraded to Buy from Sell at Citi
03/08/21 Barclays
GSX Techedu price target raised to $73 from $63 at Barclays
PFE Pfizer
$36.62 /

+0.37 (+1.02%)

NWSA News Corp.
$25.03 /

-0.7 (-2.72%)

MRNA Moderna
$123.35 /

-9.8 (-7.36%)

LUV Southwest
$60.96 /

-0.32 (-0.52%)

HMHC Houghton Mifflin
$7.11 /

+1.115 (+18.61%)

HGEN Humanigen
$21.69 /

+7.68 (+54.82%)

GSX GSX Techedu
$31.84 /

-7.17 (-18.38%)

CS Credit Suisse
$11.38 /

-1.485 (-11.54%)

CLDX Celldex
$20.50 /

-3.51 (-14.62%)

CG Carlyle Group
$36.37 /

-0.37 (-1.01%)

BA Boeing
$250.81 /

+5.96 (+2.43%)

  • 31
    Mar
  • 12
    Mar
  • 18
    Sep
  • 23
    Jul
  • 16
    Jun
  • 19
    May
  • 29
    Apr
PFE Pfizer
$36.62 /

+0.37 (+1.02%)

NWSA News Corp.
$25.03 /

-0.7 (-2.72%)

MRNA Moderna
$123.35 /

-9.8 (-7.36%)

LUV Southwest
$60.96 /

-0.32 (-0.52%)

HMHC Houghton Mifflin
$7.11 /

+1.115 (+18.61%)

GSX GSX Techedu
$31.84 /

-7.17 (-18.38%)

CS Credit Suisse
$11.38 /

-1.485 (-11.54%)

CG Carlyle Group
$36.37 /

-0.37 (-1.01%)

BNTX BioNTech
$95.74 /

+0.21 (+0.22%)

BA Boeing
$250.81 /

+5.96 (+2.43%)

PFE Pfizer
$36.62 /

+0.37 (+1.02%)

NWSA News Corp.
$25.03 /

-0.7 (-2.72%)

MRNA Moderna
$123.35 /

-9.8 (-7.36%)

LUV Southwest
$60.96 /

-0.32 (-0.52%)

HGEN Humanigen
$21.69 /

+7.68 (+54.82%)

GSX GSX Techedu
$31.84 /

-7.17 (-18.38%)

CS Credit Suisse
$11.38 /

-1.485 (-11.54%)

CG Carlyle Group
$36.37 /

-0.37 (-1.01%)

BNTX BioNTech
$95.74 /

+0.21 (+0.22%)

BA Boeing
$250.81 /

+5.96 (+2.43%)

PFE Pfizer
$36.62 /

+0.37 (+1.02%)

NWSA News Corp.
$25.03 /

-0.7 (-2.72%)

MRNA Moderna
$123.35 /

-9.8 (-7.36%)

LUV Southwest
$60.96 /

-0.32 (-0.52%)

HGEN Humanigen
$21.69 /

+7.68 (+54.82%)

GSX GSX Techedu
$31.84 /

-7.17 (-18.38%)

CS Credit Suisse
$11.38 /

-1.485 (-11.54%)

CG Carlyle Group
$36.37 /

-0.37 (-1.01%)

BNTX BioNTech
$95.74 /

+0.21 (+0.22%)

BA Boeing
$250.81 /

+5.96 (+2.43%)

Syndicate
Humanigen files to sell 5M shares of common stock » 16:13
03/29/21
03/29
16:13
03/29/21
16:13
HGEN

Humanigen

$21.66 /

+7.65 (+54.60%)

Jefferies, Credit Suisse…

Jefferies, Credit Suisse and Cantor are acting as joint book-running managers for the offering. Bryan, Garnier & Co. is acting as European lead manager for the offering, Oppenheimer & Co. is acting as lead manager for the offering and H.C. Wainwright & Co., National Securities Corporation and Roth Capital Partners are acting as co-managers for the offering.

ShowHide Related Items >><<
HGEN Humanigen
$21.66 /

+7.65 (+54.60%)

HGEN Humanigen
$21.66 /

+7.65 (+54.60%)

03/29/21 JPMorgan
Humanigen upside reaction 'somewhat overdone,' says JPMorgan
03/29/21 RBC Capital
Humanigen lenzilumab update 'an incremental positive' for Avid, says RBC Capital
03/29/21 Roth Capital
Humanigen price target raised to $35 from $25 at Roth Capital
02/23/21 JPMorgan
Humanigen initiated with a Neutral at JPMorgan
HGEN Humanigen
$21.66 /

+7.65 (+54.60%)

  • 18
    Sep
HGEN Humanigen
$21.66 /

+7.65 (+54.60%)

HGEN Humanigen
$21.66 /

+7.65 (+54.60%)

Recommendations
Humanigen upside reaction 'somewhat overdone,' says JPMorgan » 13:23
03/29/21
03/29
13:23
03/29/21
13:23
HGEN

Humanigen

$23.72 /

+9.71 (+69.31%)

After Humanigen announced…

After Humanigen announced topline results from the phase 3 trial of lenzilumab in hospitalized COVID-19 patients, JPMorgan analyst Eric Joseph said the results were in-line with his base case scenario and that "the data are limited in their differentiation from other biologic immuno-suppressive regimes available for off-label use in the indication." Though he sees the path toward an emergency use authorization for lenzilumab being "fundamentally de-risked" by the data, he sees "a moderated commercial outlook for the product" and views today's upside reaction in the shares "as somewhat overdone," Joseph tells investors. He keeps a Neutral rating on the stock and continues to view $21 per share as a fair valuation for mid-term, Joseph added. In afternoon trading, Humanigen shares are up $9.16, or 65%, to $23.15.

ShowHide Related Items >><<
HGEN Humanigen
$23.72 /

+9.71 (+69.31%)

HGEN Humanigen
$23.72 /

+9.71 (+69.31%)

03/29/21 RBC Capital
Humanigen lenzilumab update 'an incremental positive' for Avid, says RBC Capital
03/29/21 Roth Capital
Humanigen price target raised to $35 from $25 at Roth Capital
02/23/21 JPMorgan
Humanigen initiated with a Neutral at JPMorgan
01/20/21 Jefferies
Jefferies reads Humanigen COVID-19 trial change as 'sign of confidence'
HGEN Humanigen
$23.72 /

+9.71 (+69.31%)

  • 18
    Sep
HGEN Humanigen
$23.72 /

+9.71 (+69.31%)

HGEN Humanigen
$23.72 /

+9.71 (+69.31%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:08
03/29/21
03/29
12:08
03/29/21
12:08
BA

Boeing

$251.20 /

+6.35 (+2.59%)

, LUV

Southwest

$60.44 /

-0.84 (-1.37%)

, CS

Credit Suisse

$11.40 /

-1.47 (-11.43%)

, NMR

Nomura

$5.74 /

-0.885 (-13.37%)

, PFE

Pfizer

$36.59 /

+0.34 (+0.94%)

, MRNA

Moderna

$124.10 /

-9.05 (-6.80%)

, BNTX

BioNTech

$94.61 /

-0.92 (-0.96%)

, HGEN

Humanigen

$26.70 /

+12.69 (+90.58%)

, FLY

Fly Leasing

$16.86 /

+3.615 (+27.30%)

, CG

Carlyle Group

$36.49 /

-0.25 (-0.68%)

, CLDX

Celldex

$15.55 /

-8.46 (-35.24%)

, ORPH

Orphazyme

$8.79 /

-3.6 (-29.06%)

The major averages are…

ShowHide Related Items >><<
PFE Pfizer
$36.59 /

+0.34 (+0.94%)

ORPH Orphazyme
$8.79 /

-3.6 (-29.06%)

NMR Nomura
$5.74 /

-0.885 (-13.37%)

MRNA Moderna
$124.10 /

-9.05 (-6.80%)

LUV Southwest
$60.44 /

-0.84 (-1.37%)

HGEN Humanigen
$26.70 /

+12.69 (+90.58%)

FLY Fly Leasing
$16.86 /

+3.615 (+27.30%)

CS Credit Suisse
$11.40 /

-1.47 (-11.43%)

CLDX Celldex
$15.55 /

-8.46 (-35.24%)

CG Carlyle Group
$36.49 /

-0.25 (-0.68%)

BNTX BioNTech
$94.61 /

-0.92 (-0.96%)

BA Boeing
$251.20 /

+6.35 (+2.59%)

BA Boeing
$251.20 /

+6.35 (+2.59%)

03/29/21 Goldman Sachs
Boeing resuming 787 deliveries removes overhang, says Goldman Sachs
03/19/21 Susquehanna
Boeing price target raised to $300 from $250 at Susquehanna
03/15/21 Morgan Stanley
Aerospace sector upgraded to Attractive from Cautious at Morgan Stanley
03/15/21 Morgan Stanley
Boeing price target raised to $274 from $250 at Morgan Stanley
LUV Southwest
$60.44 /

-0.84 (-1.37%)

03/23/21
Fly Intel: Top five analyst upgrades
03/23/21 Argus
Southwest upgraded to Buy from Hold at Argus
03/23/21 Argus
Southwest upgraded to Buy from Hold at Argus
03/16/21 Goldman Sachs
Southwest price target raised to $69 from $47 at Goldman Sachs
CS Credit Suisse
$11.40 /

-1.47 (-11.43%)

03/29/21
Fly Intel: Top five analyst downgrades
03/29/21 BofA
Credit Suisse downgraded to Neutral from Buy at BofA
03/17/21 Kepler Cheuvreux
Credit Suisse downgraded to Hold from Buy at Kepler Cheuvreux
03/11/21 Goldman Sachs
Credit Suisse downgraded to Neutral from Buy at Goldman Sachs
NMR Nomura
$5.74 /

-0.885 (-13.37%)

03/29/21 JPMorgan
Nomura downgraded to Underweight from Neutral at JPMorgan
03/09/21 Goldman Sachs
Nomura upgraded to Buy from Neutral at Goldman Sachs
03/01/21 Citi
Nomura upgraded to Neutral from Sell at Citi
PFE Pfizer
$36.59 /

+0.34 (+0.94%)

03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
MRNA Moderna
$124.10 /

-9.05 (-6.80%)

03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
03/01/21 Chardan
Moderna price target raised to $182 from $107 at Chardan
02/26/21 Barclays
Moderna price target raised to $178 from $169 at Barclays
02/26/21 Brookline
Moderna price target raised to $205 from $180 at Brookline
BNTX BioNTech
$94.61 /

-0.92 (-0.96%)

02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
HGEN Humanigen
$26.70 /

+12.69 (+90.58%)

03/29/21 RBC Capital
Humanigen lenzilumab update 'an incremental positive' for Avid, says RBC Capital
03/29/21 Roth Capital
Humanigen price target raised to $35 from $25 at Roth Capital
02/23/21 JPMorgan
Humanigen initiated with a Neutral at JPMorgan
01/20/21 Jefferies
Jefferies reads Humanigen COVID-19 trial change as 'sign of confidence'
FLY Fly Leasing
$16.86 /

+3.615 (+27.30%)

03/19/21 Deutsche Bank
Fly Leasing price target raised to $13 from $10 at Deutsche Bank
02/26/21 Deutsche Bank
Fly Leasing downgraded to Hold with $10 target at Deutsche Bank
02/26/21 Deutsche Bank
Fly Leasing downgraded to Hold from Buy at Deutsche Bank
01/26/21 Cowen
Fly Leasing price target raised to $13 from $9 at Cowen
CG Carlyle Group
$36.49 /

-0.25 (-0.68%)

02/24/21 Deutsche Bank
Carlyle Group price target raised to $39 from $37 at Deutsche Bank
02/24/21 Barclays
Carlyle Group price target raised to $39 from $36 at Barclays
02/19/21
Fly Intel: Top five analyst upgrades
02/19/21 Credit Suisse
Carlyle Group upgraded to Outperform from Neutral at Credit Suisse
CLDX Celldex
$15.55 /

-8.46 (-35.24%)

02/23/21 H.C. Wainwright
Celldex price target raised to $36 from $25 at H.C. Wainwright
02/23/21 Cantor Fitzgerald
Celldex price target raised to $35 from $22 at Cantor Fitzgerald
10/19/20 H.C. Wainwright
Celldex price target raised to $25 from $16 at H.C. Wainwright
07/01/20 Cantor Fitzgerald
Celldex price target raised to $18 from $12 at Cantor Fitzgerald
ORPH Orphazyme
$8.79 /

-3.6 (-29.06%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
PFE Pfizer
$36.59 /

+0.34 (+0.94%)

MRNA Moderna
$124.10 /

-9.05 (-6.80%)

LUV Southwest
$60.44 /

-0.84 (-1.37%)

HGEN Humanigen
$26.70 /

+12.69 (+90.58%)

FLY Fly Leasing
$16.86 /

+3.615 (+27.30%)

CS Credit Suisse
$11.40 /

-1.47 (-11.43%)

CLDX Celldex
$15.55 /

-8.46 (-35.24%)

CG Carlyle Group
$36.49 /

-0.25 (-0.68%)

BA Boeing
$251.20 /

+6.35 (+2.59%)

  • 12
    Mar
  • 29
    Sep
  • 18
    Sep
  • 23
    Jul
  • 16
    Jun
  • 19
    May
  • 29
    Apr
PFE Pfizer
$36.59 /

+0.34 (+0.94%)

MRNA Moderna
$124.10 /

-9.05 (-6.80%)

LUV Southwest
$60.44 /

-0.84 (-1.37%)

FLY Fly Leasing
$16.86 /

+3.615 (+27.30%)

CS Credit Suisse
$11.40 /

-1.47 (-11.43%)

CG Carlyle Group
$36.49 /

-0.25 (-0.68%)

BNTX BioNTech
$94.61 /

-0.92 (-0.96%)

BA Boeing
$251.20 /

+6.35 (+2.59%)

PFE Pfizer
$36.59 /

+0.34 (+0.94%)

ORPH Orphazyme
$8.79 /

-3.6 (-29.06%)

MRNA Moderna
$124.10 /

-9.05 (-6.80%)

LUV Southwest
$60.44 /

-0.84 (-1.37%)

HGEN Humanigen
$26.70 /

+12.69 (+90.58%)

CS Credit Suisse
$11.40 /

-1.47 (-11.43%)

CG Carlyle Group
$36.49 /

-0.25 (-0.68%)

BNTX BioNTech
$94.61 /

-0.92 (-0.96%)

BA Boeing
$251.20 /

+6.35 (+2.59%)

PFE Pfizer
$36.59 /

+0.34 (+0.94%)

MRNA Moderna
$124.10 /

-9.05 (-6.80%)

LUV Southwest
$60.44 /

-0.84 (-1.37%)

HGEN Humanigen
$26.70 /

+12.69 (+90.58%)

CS Credit Suisse
$11.40 /

-1.47 (-11.43%)

CG Carlyle Group
$36.49 /

-0.25 (-0.68%)

BNTX BioNTech
$94.61 /

-0.92 (-0.96%)

BA Boeing
$251.20 /

+6.35 (+2.59%)

Recommendations
Humanigen lenzilumab update 'an incremental positive' for Avid, says RBC Capital » 10:57
03/29/21
03/29
10:57
03/29/21
10:57
CDMO

Avid Bioservices

$16.97 /

+0.13 (+0.77%)

, HGEN

Humanigen

$26.85 /

+12.84 (+91.65%)

RBC Capital analyst Sean…

RBC Capital analyst Sean Dodge notes that Humanigen (HGEN) reported "encouraging" topline results from its Phase 3 lenzilumab clinical trial, which is evaluating efficacy/safety of the drug for patients hospitalized with COVID-19. Back on February 3rd, Avid (CDMO) announced it had entered into a cGMP manufacturing agreement with Humanigen to help expand production capacity for lenzilumab, Dodge adds. The analyst believes the data update increases the chances of an eventual FDA approval, and given Avid currently only has one commercial client, the likely addition of another commercial project enhances his confidence in the longer-term revenue growth outlook. He has an Outperform rating and a $21 price target on Avid's shares.

ShowHide Related Items >><<
HGEN Humanigen
$26.85 /

+12.84 (+91.65%)

CDMO Avid Bioservices
$16.97 /

+0.13 (+0.77%)

CDMO Avid Bioservices
$16.97 /

+0.13 (+0.77%)

03/16/21 RBC Capital
RBC starts Avid Bioservices at Outperform with $21 price target
03/16/21 RBC Capital
Avid Bioservices initiated with an Outperform at RBC Capital
02/01/21 KeyBanc
Avid Bioservices price target raised to $22 from $12 at KeyBanc
11/09/20 KeyBanc
Avid Bioservices initiated with an Overweight at KeyBanc
HGEN Humanigen
$26.85 /

+12.84 (+91.65%)

03/29/21 Roth Capital
Humanigen price target raised to $35 from $25 at Roth Capital
02/23/21 JPMorgan
Humanigen initiated with a Neutral at JPMorgan
01/20/21 Jefferies
Jefferies reads Humanigen COVID-19 trial change as 'sign of confidence'
12/23/20 National Securities
Humanigen initiated with a Buy at National Securities
HGEN Humanigen
$26.85 /

+12.84 (+91.65%)

CDMO Avid Bioservices
$16.97 /

+0.13 (+0.77%)

  • 10
    Dec
  • 18
    Sep
HGEN Humanigen
$26.85 /

+12.84 (+91.65%)

CDMO Avid Bioservices
$16.97 /

+0.13 (+0.77%)

HGEN Humanigen
$26.85 /

+12.84 (+91.65%)

Hot Stocks
Humanigen trading resumes  09:55
03/29/21
03/29
09:55
03/29/21
09:55
HGEN

Humanigen

$20.30 /

+6.29 (+44.90%)

 
ShowHide Related Items >><<
HGEN Humanigen
$20.30 /

+6.29 (+44.90%)

HGEN Humanigen
$20.30 /

+6.29 (+44.90%)

03/29/21 Roth Capital
Humanigen price target raised to $35 from $25 at Roth Capital
02/23/21 JPMorgan
Humanigen initiated with a Neutral at JPMorgan
01/20/21 Jefferies
Jefferies reads Humanigen COVID-19 trial change as 'sign of confidence'
12/23/20 National Securities
Humanigen initiated with a Buy at National Securities
HGEN Humanigen
$20.30 /

+6.29 (+44.90%)

  • 18
    Sep
HGEN Humanigen
$20.30 /

+6.29 (+44.90%)

HGEN Humanigen
$20.30 /

+6.29 (+44.90%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.